中国药房2012，Vol.23Issue(9)：778-780,3.DOI:10.6039/j.issn.1001-0408.2012.09.04
临床效用指标在早期药品研发决策中的应用
Application of Clinical Utility Index in Drug R&D Decision-making in Early Stage
邹韵 1杨悦1
作者信息
- 1. 沈阳药科大学工商管理学院,沈阳110016
- 折叠
摘要
Abstract
OBJECTIVE: To quantize risk/benefit ratio of drug R&D, and to optimize drug R&D decision-making in the early stage. METHODS: The existing problems in current drug R&D decision were analyzed, and the application of clinical utility index contributed to drug R&D decision-making in the early stage. RESULTS & CONCLUSIONS: The traditional drug R&D has faced the challenge of multi-objective decision, difficulty in quantizing risk/benefit ratio, the rising cost of drug R&D. In early stage of the application of clinical utility index in drug R&D decision-making, we should quantize the multiple property evaluation of drug, calculate clinical effect of drug R&D, identify the risk and benefit of drug R&D decision-making quickly to suspend unacceptable risk and benefit early, cut down the cost of R&D and optimize the early drug R&D decision-making.关键词
临床效用指标/药品研发/决策/模拟/建模/风险/效益Key words
Clinical utility index/ Drug R&D/ Decision-making/ Simulation/ Modeling/ Risk/ Benefit分类
医药卫生引用本文复制引用
邹韵,杨悦..临床效用指标在早期药品研发决策中的应用[J].中国药房,2012,23(9):778-780,3.
